{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Early+Parkinson%27s+Disease&page=4",
    "query": {
      "condition": "Early Parkinson's Disease",
      "page": 4
    },
    "page_size": 10
  },
  "pagination": {
    "page": 4,
    "page_size": 10,
    "total_count": 87,
    "total_pages": 9,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Early+Parkinson%27s+Disease&page=5&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Early+Parkinson%27s+Disease&page=3&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-13T15:09:45.741Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04201093",
      "title": "Fixed-Dose Trial in Early Parkinson's Disease (PD)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Parkinson Disease"
      ],
      "interventions": [
        {
          "name": "Tavapadon",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AbbVie",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "40 Years to 80 Years"
      },
      "enrollment_count": 529,
      "start_date": "2019-12-13",
      "completion_date": "2024-06-28",
      "has_results": true,
      "last_update_posted_date": "2025-07-28",
      "last_synced_at": "2026-10-13T15:09:45.741Z",
      "location_count": 27,
      "location_summary": "Birmingham, Alabama • Little Rock, Arkansas • Fountain Valley, California + 24 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Fountain Valley",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Pasadena",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04201093"
    },
    {
      "nct_id": "NCT06203106",
      "title": "NYSCF Scientific Discovery Biobank",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "ALS",
        "Amyotrophic Lateral Sclerosis",
        "Alzheimer Disease",
        "Alzheimer Disease, Early Onset",
        "Alzheimer Disease, Late Onset",
        "Batten Disease",
        "Corticobasal Degeneration",
        "Dementia",
        "Frontotemporal Dementia",
        "Huntington Disease",
        "Lewy Body Disease",
        "Multiple Sclerosis",
        "Multiple System Atrophy",
        "Parkinson Disease",
        "Parkinson's Disease and Parkinsonism",
        "Progressive Supranuclear Palsy",
        "INAD",
        "Diabetes",
        "Diabetes Mellitus",
        "Diabetes Mellitus, Type 2",
        "Diabetes Mellitus, Type 1",
        "Macular Degeneration",
        "Ovarian Cancer",
        "Cervical Cancer",
        "Uterine Cancer",
        "Vaginal Cancer",
        "Vulvar Cancer",
        "PTSD",
        "Post Traumatic Stress Disorder"
      ],
      "interventions": [
        {
          "name": "Biological Sample Collection",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "New York Stem Cell Foundation Research Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "30 Days",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "30 Days and older"
      },
      "enrollment_count": 10000,
      "start_date": "2022-11-10",
      "completion_date": "2045-11-10",
      "has_results": false,
      "last_update_posted_date": "2025-03-03",
      "last_synced_at": "2026-10-13T15:09:45.741Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06203106"
    },
    {
      "nct_id": "NCT06757010",
      "title": "A Study of NE3107 in Early Parkinson's",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Parkinsons Disease (PD)"
      ],
      "interventions": [
        {
          "name": "NE3107",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "BioVie Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "45 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "45 Years to 80 Years"
      },
      "enrollment_count": 57,
      "start_date": "2025-03-26",
      "completion_date": "2026-05-31",
      "has_results": false,
      "last_update_posted_date": "2026-08-11",
      "last_synced_at": "2026-10-13T15:09:45.741Z",
      "location_count": 4,
      "location_summary": "Farmington Hills, Michigan • Amherst, New York • Morrisville, North Carolina + 1 more",
      "locations": [
        {
          "city": "Farmington Hills",
          "state": "Michigan"
        },
        {
          "city": "Amherst",
          "state": "New York"
        },
        {
          "city": "Morrisville",
          "state": "North Carolina"
        },
        {
          "city": "Canton",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06757010"
    },
    {
      "nct_id": "NCT04386317",
      "title": "Terazosin Effect on Cardiac Changes in Early Parkinson's Disease",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "REM Sleep Behavior Disorder",
        "Pre-motor Parkinson's Disease",
        "Symptomatic Parkinson Disease"
      ],
      "interventions": [
        {
          "name": "Terazosin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Cedars-Sinai Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "50 Years to 85 Years"
      },
      "enrollment_count": 15,
      "start_date": "2020-11-01",
      "completion_date": "2026-03-10",
      "has_results": false,
      "last_update_posted_date": "2026-03-02",
      "last_synced_at": "2026-10-13T15:09:45.741Z",
      "location_count": 1,
      "location_summary": "Los Angeles, California",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04386317"
    },
    {
      "nct_id": "NCT01968460",
      "title": "Safety, Tolerability and Efficacy of Two Doses of Once Daily P2B001 in Subjects With Early Parkinson's Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Parkinson's Disease"
      ],
      "interventions": [
        {
          "name": "P2B001 once daily (pramipexole 0.6 mg / rasagiline 0.75 mg),",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "P2B001 once daily (pramipexole 0.3 mg / rasagiline 0.75 mg),",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pharma Two B Ltd.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "35 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "35 Years to 75 Years"
      },
      "enrollment_count": 149,
      "start_date": "2013-12",
      "completion_date": "2015-06",
      "has_results": true,
      "last_update_posted_date": "2023-04-07",
      "last_synced_at": "2026-10-13T15:09:45.741Z",
      "location_count": 24,
      "location_summary": "Birmingham, Alabama • Los Angeles, California • Aurora, Colorado + 21 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Manchester",
          "state": "Connecticut"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01968460"
    },
    {
      "nct_id": "NCT00833690",
      "title": "Safety of Urate Elevation in Parkinson's Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Parkinson Disease"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "inosine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "The Parkinson Study Group",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "30 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "30 Years and older"
      },
      "enrollment_count": 75,
      "start_date": "2009-06",
      "completion_date": "2012-12",
      "has_results": true,
      "last_update_posted_date": "2014-06-05",
      "last_synced_at": "2026-10-13T15:09:45.741Z",
      "location_count": 16,
      "location_summary": "Los Angeles, California • Manchester, Connecticut • New Haven, Connecticut + 12 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Manchester",
          "state": "Connecticut"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Boca Raton",
          "state": "Florida"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00833690"
    },
    {
      "nct_id": "NCT00335166",
      "title": "SLV 308 and Pramipexole for Treatment of Patients With Early Parkinson Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Early Stage Parkinson Disease"
      ],
      "interventions": [
        {
          "name": "Pardaprunox",
          "type": "DRUG"
        },
        {
          "name": "pramipexole",
          "type": "DRUG"
        },
        {
          "name": "Placebo Comparator",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Solvay Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "30 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "30 Years and older"
      },
      "enrollment_count": 330,
      "start_date": "2006-11",
      "completion_date": "2008-02",
      "has_results": false,
      "last_update_posted_date": "2008-04-03",
      "last_synced_at": "2026-10-13T15:09:45.741Z",
      "location_count": 17,
      "location_summary": "Birmingham, Alabama • Oceanside, California • Oxnard, California + 13 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Oceanside",
          "state": "California"
        },
        {
          "city": "Oxnard",
          "state": "California"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Boca Raton",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00335166"
    },
    {
      "nct_id": "NCT00594165",
      "title": "An Open-Label Extension Trial to Assess the Safety of Long-Term Treatment of Rotigotine in Early-Stage Parkinson's Disease.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Early-Stage Parkinson's Disease"
      ],
      "interventions": [
        {
          "name": "Rotigotine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "UCB Pharma",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "31 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "31 Years and older"
      },
      "enrollment_count": 217,
      "start_date": "2002-06",
      "completion_date": "2008-11",
      "has_results": true,
      "last_update_posted_date": "2014-10-02",
      "last_synced_at": "2026-10-13T15:09:45.741Z",
      "location_count": 37,
      "location_summary": "Peoria, Arizona • Phoenix, Arizona • Tucson, Arizona + 34 more",
      "locations": [
        {
          "city": "Peoria",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Fountain Valley",
          "state": "California"
        },
        {
          "city": "Fresno",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00594165"
    },
    {
      "nct_id": "NCT00291265",
      "title": "Measures of Motor Impairment in Early Parkinson's Disease",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Parkinson's Disease"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "National Institute of Neurological Disorders and Stroke (NINDS)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "30 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "30 Years to 85 Years"
      },
      "enrollment_count": 10,
      "start_date": "2006-02-09",
      "completion_date": "2010-02-02",
      "has_results": false,
      "last_update_posted_date": "2017-07-02",
      "last_synced_at": "2026-10-13T15:09:45.741Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00291265"
    },
    {
      "nct_id": "NCT03775096",
      "title": "Adrenergic Blockers for Cardiac Changes in Early Parkinson's Disease (Protocol 53136)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "REM Sleep Behavior Disorder",
        "Pre-motor Parkinson Disease",
        "Symptomatic Parkinson Disease"
      ],
      "interventions": [
        {
          "name": "Carvedilol",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Michele Tagliati, MD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "50 Years to 85 Years"
      },
      "enrollment_count": 15,
      "start_date": "2019-04-04",
      "completion_date": "2026-07-01",
      "has_results": false,
      "last_update_posted_date": "2026-03-02",
      "last_synced_at": "2026-10-13T15:09:45.741Z",
      "location_count": 1,
      "location_summary": "Los Angeles, California",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03775096"
    }
  ]
}